key: cord-0077544-66hu4pkd
authors: Al-Obaidi, Mohanad MM.; Gungor, Ahmet B.; Nematollahi, Saman; Zangeneh, Tirdad T.; Bedrick, Edward J.; Johnson, Katherine M.; Adegbija, Nicole; Alam, Ruhaniyah; Rangan, Pooja; Heise, C. William; Ariyamuthu, Venkatesh K.; Shetty, Aneesha; Qannus, Abd Assalam; Murugapandian, Sangeetha; Ayvaci, Mehmet MS.; Anand, Prince Mohan; Tanriover, Bekir
title: EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 B.1.617.2 (COVID-19 DELTA VARIANT) INFECTION
date: 2022-04-12
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofac186
sha: 88d75cd419291ed914dc834a46b73bb0ba8d38f7
doc_id: 77544
cord_uid: 66hu4pkd

BACKGROUND: Real-world data on the effectiveness of neutralizing Casirivimab-Imdevimab monoclonal antibody (Cas-Imd mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among high-risk patients may inform the response to future SARS-CoV-2 variants. METHODS: This study covers an observational retrospective data analysis in Banner Health Care System sites, mainly in Arizona. During the study period, the prevalence of SARS-CoV-2 Delta variant was between 95% and 100%. Out of 29,635 patients who tested positive for COVID-19 between 8/1/2021 and 10/30/2021, in Banner Health Care System, the study cohort was split into 4213 adult patients who received Cas-Imd mAb (1200 mg) treatment compared to a propensity-matched 4213 untreated patients. The primary outcomes were the incidence of all-cause hospitalization, intensive care unit (ICU) admission, and mortality within 30 days of Cas-Imd mAb administration or COVID-19 Delta variant infection. RESULTS: Compared to the propensity matched untreated cohort, the Cas-Imd mAb cohort had significantly lower all-cause hospitalization (4.2% vs 17.6%; difference in percentages and 95% confidence interval [CI] -13.4 [-14,7, -12.0], P <.001), ICU admission (0.3% vs 2.8%; difference and CI -2.4 [-3.0, -1.9], P <.001), and mortality (0.2% vs 2.0%; difference and CI -1.8 [-2.3, -1.3], P <.001) within 30 days. The Cas-Imd mAb treatment was associated with lower rate of hospitalization (hazard ratio [HR], 0.22; 95% CI, 0.19-0.26; P <.001) and mortality (HR, 0.11; 95% CI, 0.06-0.21; P<.001). CONCLUSIONS: Cas-Imd mAb treatment was associated with a lower hospitalization rate, ICU admission, and mortality within 30 days among patients infected with COVID-19 Delta variant.

A C C E P T E D M A N U S C R I P T percentages between cohorts and related 95% confidence intervals were reported along with the 1 Mcnemar test's p-value. Calculations were performed using the R package exact2x2. In addition, Kaplan-2 Meier survival analysis was performed to evaluate the difference in time to all-cause hospitalization and 3 mortality rates (using Stata 17, StataCorp College Station, Texas). 4

For secondary continuous outcomes, hospital LOS, and ICU LOS, mean and standard deviation of the 5 outcome were reported. Individuals who were not hospitalized were considered as they had zero LOS in 6 both outcomes. A two-part generalized linear mixed model with random effect for matched pairs was 7 fitted to compare LOS across cohorts among patients who have LOS greater than zero, by evaluating the 8 model's fixed effects for Cas-Imd mAb use. The estimated coefficient, 95% confidence interval of the 9 coefficient, and the statistical significance of the fixed antibody effect were reported. The R package 10

GLMMadaptive was used to fit the mixed model. 11

For our categorical secondary outcomes, intensity of oxygen therapy and AKI stages during 12 hospitalization, counts, and percentages were reported. The subcategories for both variables were 13 grouped into two clinically meaningful categories due to the small sample size. Wald test of no 14 differences was conducted to compare the distributions for treatment and control cohort cases, given a 15 hospitalized patient. 16 An additional analysis was conducted to assess how the primary outcomes differ based on COVID-19 17 messenger RNA (mRNA) vaccination status. An individual was considered fully vaccinated if 14 days had 18 passed after their final dose of the vaccine before the index date. First, the Stuart-Maxwell test for 19 marginal homogeneity was used to compare vaccination status between the treatment and control 20 cohorts. Then, the post-match treatment and control cohorts were combined and then split into 21 vaccinated and unvaccinated cohorts, excluding the individuals with missing vaccination status. The 22 optimal matching method was used to rematch both vaccinated and unvaccinated cohorts separately 23 A C C E P T E D M A N U S C R I P T 8 for the propensity score calculation, using the same model in the previous analysis. 31 Following the 1 optimal rematching, 949 pairs (n=1898) were matched in the vaccinated cohort, and 2732 (n=5464) 2 were matched in the unvaccinated cohort. Primary outcome counts and percentages with Clopper-3

Pearson confidence intervals were reported. Finally, the hazard ratio for the effect of Cas-Imd mAb 4 treatment on time to primary outcomes was calculated using a Cox proportional hazards model adjusted 5

for COVID-19 mRNA vaccination status. 6

Missing data: 7 Data on 22 (2.4% of hospitalized) patients for intensity of oxygen therapy, 26 (2.8% hospitalized) 8 patients for serum creatinine and AKI categories, and 461 (5.5% of the study cohort) patients for 9 vaccination status was missing. Observations with missing data on secondary outcomes were considered 10 free of the outcome for their respective statistical tests. 11

The Patient Characteristics 13 Table 1 shows the characteristics of the Cas-Imd mAb and untreated control cohorts before and after 14 propensity matching. All post-propensity matching covariate SMDs were below a 0.05 threshold, 15

indicating an optimal matching ( Figure 2 ). In the post-propensity matched cohort, the median age of the 16

Cas-Imd mAb treatment arm was 50 (interquartile range [IQR]; 34-64); 55.9% were female; 67.8% were 17 White race; some of the high-risk characteristics were age ≥65 (30.6%), BMI ≥35 (35.3%), diabetes 18 mellitus (17.6%), chronic lung disease (18.2%), kidney disease any stage (8.5%), and human 19 immunodeficiency virus infection (HIV) / acquired immunodeficiency syndrome (AIDS) (5.6%). The 20 median time from COVID-19 PCR positivity to infusion was 1 day (IQR: 0, 2 days) in the Cas-Imd mAb 21 treatment cohort, shown in Supplemental Figure S2 . In a subgroup analysis based on number of days 22

from COVID-19 PCR positivity to Cas-Imd mAb infusion, we categorized time to mAb infusion variable as 1 <2 vs ≥2 days and as <3 vs ≥3 days and calculated the proportion of patients who are hospitalized and 2 died in the mAb treated cohort (Supplemental Table S1 ). The results show no significant difference 3 regarding the hospitalization and mortality in both categories. 4

The Primary and Secondary Outcomes 5 Table 2 and Supplemental Table S2 show the results of the primary and/or secondary outcomes within 6 30 days in the post-propensity matched cohorts. Compared to the untreated control cohort, the 7 percentage of patients with all-cause hospitalizations in the Cas-Imd mAb cohort was 4.2% with 95% CI 8 of (3.6%-4.8%) vs 17.6% (16.4%-18.7%; P < .001); the percentage of patients with ICU admission in the 9

Cas-Imd mAb was 0.3% (95% CI: 0.25%-0.5%) vs 2.8% (95% CI: 2.3%-3.3%; P < .001); the proportion of 10 patients with all-cause mortality was 0.2% (95% CI: 0.1%-0.4%) vs 2.0% (95% CI: 1.6%-2.4%; P < .001). compared to the untreated control cohort, the mean (standard deviation [SD]) for hospital LOS was 5.3 20 (5.3) days in the Cas-Imd mAb cohort vs 6.9 (7.9) days, (P = .06); the mean (SD) for ICU LOS was 3.6 (4.8) 21 days in the Cas-Imd mAb cohort vs 3.8 (5.3) days, (P = .85). The GLMM model that estimates the mean 22

ratio of cohorts showed that upper 95% confidence intervals of both hospital LOS and ICU LOS outcomes 23

include one. The percentage of the highest intensity oxygen requirements (including mechanical 1 ventilation/CPAP-BPAP/high flow oxygen) , were lower in the Cas-Imd mAb cohort (25.8% vs 42.5%; P < 2 .001) compared with the untreated control cohort. The percentage of the KDIGO AKI Stage 2-3 in the 3

Cas-Imd mAb cohort (1.4%) was lower than in the untreated cohort (6.1%; P < .001). 4 Table 3 shows the primary outcomes for the propensity rematched Cas-Imd mAb treated, and untreated 6 cohorts stratified by vaccination status. The study cohort received COVID-19 mRNA vaccines from Pfizer-7 BioNTech (67.9%) and Moderna (32.1%). The prevalence of COVID-19 mRNA vaccination was lower 8 among study participants (28.3% in the Cas-Imd mAb cohort vs 23.8% in the control untreated cohort; P 9 < .001) as compared to the state and national reported vaccination rates. In terms of the primary 10 outcomes, the lowest all-cause hospitalization (1.7%) / ICU admission (0.0%)/ mortality (0.0%) rates 11 were observed in the vaccinated Cas-Imd mAb treatment cohort while the highest all-cause 12 hospitalization (23.3%)/ ICU admission (3.7%)/ mortality (2.3%) rates were encountered in the 13 unvaccinated untreated cohort. The primary outcomes were similar between the Cas-Imd mAb treated 14 unvaccinated cohort and the untreated vaccinated cohort. In multivariable Cox proportional hazards 15 models, Cas-Imd mAb treatment and COVID-19 mRNA vaccination were independently associated with 16 lower rate of all-cause hospitalization (hazard ratio [HR], 0.22; 95% CI, 0.19-0.26; P < .001 vs HR, 0.23; 17 95% CI, 0.18-0.30; P < .001) and mortality (HR, 0.11; 95% CI, 0.06-0.21; P < .001 vs HR 0.37; 95% CI, 0.20-18 0.70; P = .02), respectively. 19

This study is one of the largest real-world studies, reporting the use of Cas-Imd mAb in reducing 21 mortality and hospitalization among high-risk populations during the pandemic period when infections 22

were caused predominantly by the COVID 19 Delta variant. 32 Our study includes a diverse population of 23

adults made up of approximately 20% Hispanic, 5% Black, and 1.5% American Indian. The untreated 1 cohort was also more predisposed to higher oxygen requirement and mechanical ventilation and 2 developed higher AKI stages than the Cas-Imd mAb group. 3

Cas-Imd efficacy against SARS-CoV 2 was shown previously in a clinical trial with COVID-19 patients who 4 received Cas-Imd mAb having lower SARS-CoV-2 viral loads and hospitalization. 14 Another recent study 5 from the Mayo Clinic showed that administration of Cas-Imd mAb was associated with a lower risk of 6 hospitalization in high-risk populations; 22 however, that study included a smaller number of patients (N 7 = 1392) during the period pre-dating the Delta variant spread compared to our investigation. In addition, 8

we demonstrate that the rates of 30-day ICU admission and all-cause mortality are significantly lower in 9 the Cas-Imd mAb treated group compared to previous studies. 10

In our subgroup-analysis based on vaccination status, we found that Cas-Imd mAb retained its efficacy in 11 lowering the rates of hospitalizations, ICU admissions, and all-cause mortality and endured its effect 12 even when the individual was fully vaccinated, but the effect size was smaller compared to the 13 unvaccinated cohort. Our study shows that approximately 25% of the propensity-matched population, 14 mainly from Arizona, were fully vaccinated, which is a number lower than the one written by the Arizona 15 Department of Health Services (AZDHS). 33 Such difference in the number of vaccinated populations 16 could be either secondary to the population's underlying characteristics that visited our hospital system 17 or secondary to lacking data of reported vaccinations. Moreover, our cohort had a higher percentage of 18 hospitalizations and deaths than the same period reported by AZDHS. 33 This could be related to the 19 high-risk population included in the study as we matched our controls with the Cas-Imd mAb cohort on 20 our institutional monoclonal antibody eligibility criteria, or to a lesser extent because of the included 21 population from the states of Montana and Colorado. 19, 34 Similar to previous reports 35 , our study shows 22

that fully vaccinated adults (not boosted) had significantly reduced hospitalization, ICU admission, and 1 death compared to the unvaccinated cohort. 2

For the study's secondary outcomes, patients receiving Cas-Imd mAb had significantly reduced oxygen 3 requirements and AKI, including the need for renal replacement therapy. The findings of our study 4 corroborate with other randomized placebo-controlled trials that reported the use of other mAb 5 products reduced the risk of hospitalization and death in high-risk patients with mild to moderate 6 COVID-19 infections. 13 7 This study has significant implications for treating COVID-19 and preventing its complications, as we 8

show that delivering monoclonal antibodies directed towards a SARS-CoV-2 Delta variant can 9 significantly lower hospitalization rates, ICU stay, and all-cause mortality. The Omicron variant has 10 spread very quickly since December 2021, hence, there exists a pandemic with mainly Omicron variant 11 coinciding with declining incidence of Delta variant infections among newly infected patients. 36 It is 12 crucial to know predominantly which variants are causing most infections in order to administer 13 appropriate monoclonal antibodies for patients infected with SARS-CoV-2 (i.e., Cas-Imd mAb for the 14 Delta variant and sotrovimab for the Omicron variant). This study highlights the role of mAb in reducing 15 COVID-19 associated complications, a similar approach can be used to assess the effectiveness of other 16 mAb or for other SARS-Cov-2variants. Furthermore, our results show that irrespective of COVID-19 17 vaccination status, receiving monoclonal antibodies led to significantly reduced hospitalization rates, ICU 18 stays, and all-cause mortality, which is essential in treating breakthrough infections. Such findings have 19 implications for unvaccinated individuals and immunocompromised individuals who will have 20 attenuated immune responses to vaccines and may benefit from passive immunity for the treatment of 21 COVID-19. 22

Our paper has several strengths, including a large sample size from an extensive hospital network 1 system that evaluated over 8400 patients (the largest reported real-world experience) with analysis 2 capturing the Delta variant period exclusively. This includes patients in both rural and urban settings 3 with excellent representation of minority groups. Moreover, the study matched patients according to 4 different risk factors that minimized bias by utilizing optimal propensity score matching. We also 5 imported the vaccination data from the Arizona State Immunization Information System. 6

The limitations of our study include the retrospective design, which may be associated with reporting 7 and selection biases, and the lack of information regarding possible hospitalizations and deaths that 8 occurred outside of the Banner Health. Lack of information about previous infections and possible 9 missing immunization information limits further interpretation of the benefits of mAb based on previous 10 immune status. In addition, a diverse subgroup of patients with hematopoietic stem-cell or solid organ 11 transplants were not included as a separate category in the propensity analysis due to small sample size; 12 such patients are known to have poorer outcomes and more likely to be referred to mAb treatment. Kidney Disease Improving Global Outcomes. 4 * The Clopper-Pearson method was used to calculate 95% confidence intervals for the outcome 5 percentages using the R package (Exactci). 6 **Exact McNemar's test was used to compare the percentage difference between the treatment and 7 control cohorts. 8 ***Comparison between two continuous variables in paired data was calculated using R package 9

GLMMadaptive for a fixed treatment effect from a two-part mixed model. Health COVID-19 Treatment.  2   Supplemental Tables:  3   Supplemental Table S1a . The proportion of patients hospitalized and died in the Casirivimab-Imdevimab 4 monoclonal antibody (Cas-Imd mAb) cohort by the time to infusion days category (stratified into <2 days 5 vs ≥2 days). 6

Supplemental Table S1b . The proportion of patients hospitalized and died in the Casirivimab-Imdevimab 7 monoclonal antibody (Cas-Imd mAb) cohort by the time to infusion days category (stratified into <3 days 8 vs ≥3 days). 9

Supplemental Table S2 . The primary outcomes in the post-propensity score-matched cohorts at 14-days 10 of index date. Imdevimab monoclonal antibody (Cas-Imd mAb) treatment cohort vs the control untreated cohort. 27 Figure S4 . Cumulative proportion of the patients died during study period by the Casirivimab-Imdevimab 28 monoclonal antibody (Cas-Imd mAb) treatment cohort vs the control untreated cohort. 29 A C C E P T E D M A N U S C R I P T Figure S5a . Cumulative proportion of the patients with pulse ox ≥ 96% hospitalized during study period 1 by the Casirivimab-Imdevimab monoclonal antibody (Cas-Imd mAb) treatment cohort vs the control 2 untreated cohort. 3 Figure S5b . Cumulative proportion of the patients with pulse ox < 96% hospitalized during study period 4 by the Casirivimab-Imdevimab monoclonal antibody (Cas-Imd mAb) treatment cohort vs the control 5 untreated cohort. 6 Figure S6a . Cumulative proportion of the patients with pulse ox ≥ 96% died during study period by the 7

Casirivimab-Imdevimab monoclonal antibody (Cas-Imd mAb) treatment cohort vs the control untreated 8 cohort. 9 Figure S6b . Cumulative proportion of the patients with pulse ox < 96% died during study period by the 10 Casirivimab-Imdevimab monoclonal antibody (Cas-Imd mAb) treatment cohort vs the control untreated 11 cohort. 

An interactive web-based dashboard to track COVID-19 in real time. The 2 Lancet Infectious diseases

SARS-CoV-2 Variant Classifications and Definitions

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass 7

Vaccination Setting

Covid-19 Breakthrough Infections in Vaccinated Health 9

Waning of BNT162b2 Vaccine Protection against SARS-11

CoV-2 Infection in Qatar

Waning Immune Humoral Response to BNT162b2 Covid-19

Vaccine over 6 Months

Monitoring Incidence of COVID-19 Cases

and Deaths, by Vaccination Status -13 U.S. Jurisdictions

Effect of early treatment with fluvoxamine on risk 18 of emergency care and hospitalisation among patients with COVID-19: the TOGETHER 19 randomised, platform clinical trial

US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes First Oral 21

Antiviral for Treatment of COVID-19

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-1

REGN-COV2, a Neutralizing Antibody Cocktail, in 3 Outpatients with Covid-19

US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes New Long

Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals

announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-8 antibodies-pre-exposure

Not All Monoclonal Antibodies for Coronavirus Disease

US Food and Drug Administration. Fact sheet for healthcare providers: emergency use 12 authorization (EUA) of bamlanivimab and etesevimab

US Food and Drug Administration. Fact sheet for health care providers. Emergency use 15 authorization (EUA) of bamlanivimab

Fact sheet for healthcare providers: emergency use 18 authorization (EUA) of REGEN-COV (casirivimab and imdevimab)

US Food and Drug Administration.. Fact sheet for healthcare providers: emergency use 21 authorization (EUA) of sotrovimab

COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities

Casirivimab-Imdevimab treatment is associated with 26 28

Optimal Full Matching and Related Designs via Network Flows

Nonparametric Preprocessing for Parametric

Relative Performance of Propensity Score Matching Strategies 18 for Subgroup Analyses

Arizona Department of Health Services. AZDHS | COVID-19 Vaccine Administration Data

Factors associated with hospital admission and critical illness 24 among 5279 people with coronavirus disease

New COVID-19 Cases and Hospitalizations Among 27